Smith & Nephew Regulatory News (SN.)

Reason for the notification

Initial notification /Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Smith & Nephew plc

LEI

213800ZTMDN8S67S1H61

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

Smith & Nephew plc ordinary shares of USD 0.20 each

Identification code

ISIN: GB0009223206

Nature of the transaction

Purchase of ordinary shares through the Company's Dividend Re-Investment Plan following the 2023 interim dividend payment on 1 November 2023.

Date of Transaction

2023 - 11 - 1

Place of Transaction

London Stock Exchange (XLON)

Name

(Position)

Director / PDMR

Price

Volume

Aggregated information

Helen Barraclough

(Group General Counsel and Company Secretary)

PDMR

£9.24546

378.63846

N/A Single Transaction

Bradley Cannon

(President, Global Orthopaedics)

PDMR

£9.24546

4.70426

N/A Single Transaction

Paul Connolly

(President, Global Operations)

PDMR

£9.24546

95.16781

N/A Single Transaction

Phil Cowdy

(Chief Corporate Development & Corporate Affairs Officer)

PDMR

£9.24546

2.52246

N/A Single Transaction

Mizanu Kebede

(Chief Quality & Regulatory Affairs Officer)

PDMR

£9.24546

50.47884

N/A Single Transaction

Deepak Nath

(Chief Executive Officer)

Director

£9.24546

1,275.12874

N/A Single Transaction

Alison Parkes

(Chief Compliance Officer)

PDMR

£9.24546

47.98799

N/A Single Transaction

Scott Schaffner

(President, Sports Medicine)

PDMR

£9.24546

722.89052

N/A Single Transaction